Schroder Investment Management Group Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Schroder Investment Management Group lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,286,141 shares of the biopharmaceutical company's stock after purchasing an additional 282,787 shares during the period. Schroder Investment Management Group owned about 0.18% of Gilead Sciences worth $210,348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Southland Equity Partners LLC grew its position in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after purchasing an additional 110 shares in the last quarter. Berkshire Bank grew its position in Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 111 shares during the period. CFO4Life Group LLC grew its holdings in shares of Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock worth $394,000 after purchasing an additional 112 shares during the period. Howe & Rusling Inc. increased its position in shares of Gilead Sciences by 2.5% during the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 115 shares during the last quarter. Finally, GHP Investment Advisors Inc. raised its holdings in Gilead Sciences by 1.1% in the 4th quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company's stock valued at $1,049,000 after buying an additional 122 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Remove Ads

Gilead Sciences Stock Performance

NASDAQ:GILD traded down $0.77 during trading hours on Tuesday, reaching $111.28. 6,284,006 shares of the company's stock were exchanged, compared to its average volume of 7,287,905. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $138.58 billion, a price-to-earnings ratio of 300.76, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a 50-day moving average of $105.88 and a 200 day moving average of $95.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.84%. The ex-dividend date was Friday, March 14th. Gilead Sciences's payout ratio is currently 854.05%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.